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Abstract 
 
Detection of osteogenic differentiation is crucial for bone tissue engineering. 
Despite established standard end point assays, there is increasing demand for 
methods allowing non-invasive kinetic differentiation monitoring. Reporter gene 
assays employing tissue-specific promoters and suitable reporter genes fulfill 
these requirements. Many promoters, however, exhibit only weak cis-activating 
potential, thus limiting their application to generate sensitive reporter gene 
assays. Therefore, the aim of this study was to design a reporter gene assay 
employing elements of the murine osteocalcin promoter coupled to a viral 
enhancer for signal amplification. Additionally, the system’s practicability was 
enhanced by introducing a secreted luciferase as a quantifiable reporter gene. 
The constructs were tested in C2C12 cells stimulated with recombinant human 
bone morphogenetic protein 2 (rhBMP2) for osteogenic differentiation in 2D and 
3D culture. 
Osteogenic differentiation was confirmed by standard assays for osteogenesis. 
The reporter gene signal was detected through a secreted luciferase or 
fluorescence microscopy for enhanced yellow fluorescent protein. The 
constructs exhibited strong activation upon treatment with rhBMP2. Weak 
background expression was observable in negative controls, attributed to the 
pan-active viral enhancer. In conclusion, a novel enhancer/tissue-specific 
promoter combination allows specific signal-amplified, kinetic monitoring of 
osteogenic differentiation in a non sample-destructive manner. 
Keywords 
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 3 
luciferase 
 
Introduction 
 
All present bone regeneration approaches intend to induce cellular differentiation as a 
central criterion, i.e. the bone forming osteoblast phenotype. The assessment of the 
successful acquirement of this phenotype is mandatory in validating the therapeutic 
benefit of newly devised methods or treatment options. Today, several standard 
assays have been established providing the viable information of successfully induced 
osteogenic differentiation to the researcher (e.g. in vitro or in vivo enzymatic alkaline 
phosphatase assay (1), in vivo ectopic bone formation assay (2) and bone matrix 
specific staining methods like von Kossa (3) and Alizarin red staining). Furthermore, 
PCR quantifiable or antibody detectable differentiation specific markers (4-8) seem to 
provide more than a satisfying array of diagnostic tools for the detection of 
osteogenesis.  
None of these methods, however, are suitable for highly sensitive and quantifiable on-
line monitoring without the need for sample-destructive processing. The necessity of 
obtaining this kind of data becomes obvious in large-scale osteoinductive substance 
screening, during ex vivo stem cell differentiation or while monitoring the progression 
of bioreactor constructs towards bone-like tissue. In large-scale screening assays, the 
option of on-line monitoring is crucial for identification of lead compounds. Ex vivo 
cellular therapies and bioreactor approaches rely on the optimization of culturing 
methods to force the cells towards osteogenic differentiation. Assay technologies 
offering this information could either reduce sample number and thus labour time for 
large scale screening assays and provide non-invasively obtained information on the 
status of preconditioned stem cells or bioreactor constructs prior to implantation. 
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Additionally, these systems could refine in vivo testing in animals, thus substantially 
reducing animal experiments carried out to test the osteoinductive capacity of future 
drugs and therapeutic approaches. 
A well-known method derived from the genetic toolbox could meet these requirements, 
namely the reporter gene assay that has been originally used for the identification and 
characterization of endogenous gene-regulatory (cis-acting) sequences. Detailed 
insights into the signal transduction cascades and gene-regulatory mechanisms 
underlying osteogenesis provided several tissue-specific promoter elements that have 
already been partially exploited to design reporter-vectors (9-11) that employ 
fluorescent or bioluminescent reporter genes. Furthermore, not only information on 
differentiation but also on cellular viability can be obtained, since this type of assay 
relies on the transcriptional machinery of viable cells, ceasing its function upon cellular 
death. 
Osteocalcin (12, 13), a genuine marker-gene transcribed by differentiated osteoblasts 
with its extensively studied and precisely described promoter sequence (9, 12, 14) 
offers regulatory sequences that can be used to design novel reporter gene constructs 
for the detection of osteogenesis. The main limitation of its proximal promoter 
sequence, however, is its generally low transactivation potential. Therefore, this 
promoter reaches only low expression levels when applied ectopically to drive the 
expression of a reporter gene. Strategies to overcome this limitation have been studied 
in previous efforts, such as the artificial multimerization of short specific regulatory 
sequences of this promoter like the multimerized osteoblast specific element 2 
(6xOSE2) (10), enabling the design of a functional reporter gene assay for osteocalcin 
expression. This study, in contrast to the strategy described above, aimed at the 
generation of an artificial, chimeric cis-acting regulatory sequence for signal 
amplification through combination of a pan-active viral enhancer with a tissue specific 
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promoter element. Taking the relatively low transcriptional activation potential of the 
murine osteocalcin 2 promoter (mOG2P) into account, the primary objective of this 
work was to investigate whether the cytomegalovirus immediate early enhancer 
(CMVE) (15, 16) is capable of amplifying specific expression. The CMVE, as already 
reported (17, 18), can be used to amplify expression from cell-type specific, weak 
endogenous promoters, but with different impact on specificity depending on the 
employed promoter (19). 
The design of constructs that employ reporter genes suitable for quantification without 
sample destructive processing and preferably suitable for real-time monitoring of 
osteoblastic differentiation was the secondary aim of this study in order to expand the 
range of application of our system to bioreactor monitoring. Therefore, we selected a 
novel secreted bioluminescent luciferase from the copepod Metridia longa (MetLuc) 
(20), which can be simply assayed and absolutely quantified by medium sampling, thus 
offering bioluminescence quantification without manipulation of the culture and under 
optimal imaging conditions. 
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Materials and Methods 
 
Growth factors 
 
Recombinant human (CHO-derived) rhBMP2 (InductOS) was purchased from Wyeth 
(Madison, NJ, USA). Recombinant human FGF2 (Escherichia coli derived) and 
recombinant human VEGF-A (Escherichia coli derived) were purchased from 
Peprotech (Rocky Hill, NJ, USA).  
 
 
Reporter plasmids and chimeric cis-acting elements 
 
All PCR synthesis reactions were carried out using a Hot-Taq polymerase enzyme 
(PeqLab Biotechnologie GmBH, Erlangen, Germany) according to the manufacturer’s 
instructions using the appropriate annealing temperatures for each of the outlined 
primer pairs. The proximal murine osteocalcin-2 promoter fragment (mOCP) (ranging 
from –174 to +3 relative to the transcriptional start site) was amplified from the plasmid 
pDRIVE-OG2 (m) v08 purchased from InvivoGen (San Diego, CA, USA) using the 
primers mOCPs1 (GATGGATCCCCTGCAGGGCCCACTAGT) and mOCPas 
(GATAAGCTTGGTGTCTGCTAGGTGTGC) for the unenhanced control reporter 
plasmid pmOCP-EYFPHis and mOCPs2 
(CCAATTCGGATCTGTCCTGCAGGGCCCACTAGT) and mOCPas for subsequent 
fusion PCR with the cytomegalovirus immediate early enhancer (CMVE). The CMVE 
fragment (ranging from –524 to –120) was amplified from the plasmid pCDNA3 
(Invitrogen, Lofer, Germany) using the primers CMVs 
(GATAGATCTGCAGGCGTTACATAACTTACGG) and CMVas 
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(ACAGATCCGAATTGGGTGAAAACAAACTCCCATTGA). 
The purified PCR fragments were employed in equimolar concentrations for a ligation 
PCR reaction using the primer overhangs (underlined in the primer sequences) for 
hybridization and the primers mOCPs and CMVas for subsequent amplification. The 
generated element was cloned into the BglII/HindIII digested pCDNA3 vector. The 
mOCP fragment from the first mOCPs1/mOCPas reaction was cloned into the 
BglII/HindIII digested pcDNA3 vector. The reporter genes EYFPHis and MetLuc were 
then ligated into the multiple cloning site of the intermediate pcDNA3-CMVE/mOCP 
plasmid to produce the reporter plasmids pCMVE/mOCP-EYFPHis and 
pCMVE/mOCP-MetLuc (Figure 1, A, B). The unenhanced control reporter plasmids 
pmOCP-EYFPHis (Figure 1, C) and pmOCP-MetLuc (Figure 1, D) were produced by 
ligation of EYFPHis or MetLuc into the multiple cloning site of the mOCP containing 
pCDNA3 intermediate plasmid. The EYFPHis fragment was created by HindIII/EcoRI 
digestion of the pEYFP (Clontech, Palo Alto, CA, USA) derivate pEYFPHis. The 
MetLuc fragment was generated by HindIII/XbaI or HindIII/NotI restriction digest of the 
pMetLuc reporter plasmid purchased from Clontech. All designed plasmids were 
verified by control restriction digests and sequenced (data not shown). 
 
 
Cell culture and transient transfection 
 
The mouse C3H muscle myoblast precursor cell line C2C12 (#ACC565), purchased 
from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany) were cultured in Dulbecco’s modified eagle’s medium 
(DMEM) (Sigma Aldrich, Vienna, Austria) containing 4.5 g/L D-Glucose, supplemented 
with 2 mM L-glutamine (Sigma Aldrich, Vienna, Austria) and 5% fetal calf serum (FCS) 
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(Lonza Ltd, Basel, Switzerland) (21). 
For the testing, cells were seeded into 24-well plates at a cell density of 0.5x105/well 
24-hours prior to transfection (2.8x104/cm2). The next day, these cells were either 
transfected with 2 µg of the pCMVE/mOCP-EYFPHis reporter plasmid or with 2 µg of 
the unenhanced control reporter plasmid pmOCP-EYFPHis for fluorescence readout. 
Co-transfection with 1 µg of the plasmids pmOCP-MetLuc or pCMVE/mOCP-MetLuc 
with 1 µg of the internal control plasmid pCBR (Promega, Madison, WI, USA) was 
carried out for subsequent bioluminescence readout. Another co-transfection using 1 
µg pMetLuc-Control (Clontech) and 1 µg of pCBR was carried out in order to generate 
the positive control samples required to calculate expression capacity relative to the 
control plasmids SV40 promoter. All transfections were carried out using Lipofectamine 
2000 (Invitrogen, Lofer, Germany). The medium was changed 4 hours after 
transfection to remove the remaining DNA/liposome complexes. 
 
 
Secreted osteocalcin reporter gene assay in 2D culture  
 
A medium change to serum reduced DMEM (1% FCS) was carried out in all wells 24 
hours after transfection. The fluorescent reporters pmOCP-EYFPHis and 
pCMVE/mOCP-EYFPHis were studied using 0 ng/ml and 500 ng/ml of rhBMP2. 
Further characterization was then carried out using the systems pmOCP-MetLuc and 
pCMVE/mOCP-MetLuc for bioluminescent quantification and comparison of produced 
signal intensities with or without CMV-enhancer. Direct comparison of mOCP and 
CMVE/mOCP activity was carried out using 0 ng/ml, 100 ng/ml and 300 ng/ml rhBMP2, 
followed by a detailed characterization of pCMVE/mOCP-MetLuc. For these 
experiments, the medium was supplemented with 50, 100 and 300 ng/ml of rhBMP2 
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or with the described growth factor controls FGF2 and VEGF-A or left unsupplemented 
as negative control. The cells were induced for 5 days with the described 
supplemented culture media before readout without medium change. A medium 
change was carried out in the pmOCP-MetLuc and pCMVE/mOCP-MetLuc transfected 
wells 24 hours before supernatant sampling (50 µl samples) in order to reduce 
background activity potentially present due to initial expression before specific 
induction. 
 
 
Secreted osteocalcin reporter gene assay in 3D culture  
 
C2C12 cells were transfected in 2D culture prior to incorporation into fibrin clots with 
the pCMVE/mOCP-MetLuc reporter plasmid (according to 2D culture transfection 
protocol). 24h after transfection, the cells were mixed into fibrin clots (Tisseel, Baxter) 
at cell density of 106 cells/clot (200 µl fibrin, ø 7.4mm, height 4mm) through 
resuspension of the cells into the thrombin (4IU/ml) component before mixing with the 
fibrinogen component (final concentration: 12,5 mg/ml fibrinogen). The fibrinogen 
component was supplemented with 1 µg InductOS rhBMP2 (final concentration in clot 
5 µg/ml rhBMP2) in the osteoinduction group. No growth factor was added in the 
control group. The clots were then cultured in serum-reduced medium (1% FCS) for 6 
days. A medium change was carried out 24h before sampling. 50 µl of supernatant 
surrounding the clot was then sampled 24h later for readout according to the 2D 
reporter gene assay protocol.  
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Fluorescence microscopy 
 
The pmOCP-EYFPHis and pCMVE/mOCP-EYFPHis transfected wells were subjected 
to live fluorescence microscopy using a confocal laser scanning microscope (CLSM; 
Zeiss, Oberkochen, Germany) with a 488 nm laser for excitation and a 520 nm long 
pass filter for emission detection of the fluorescent reporter gene EYFP. A second 
channel using 488 nm excitation without emission filter was employed to generate 
phase contrast microscopy like light microscopy overlays to document the transfection 
efficacy and reporter plasmid activity relative to the total cell numbers that were 
photographed. The depicted images represent overlays of these channels. 
 
 
Secreted Metridia Luciferase assay 
 
50 µl of supernatant from the pmOCP-MetLuc, pCMVE/mOCP-MetLuc and pMetLuc-
Control transfected wells covered with 50 µl 1x PBS were stored at -80°C until 
processing. Metridia Luciferase activity was assessed in the 50 µl supernatant samples 
after thawing using the Secreted Luciferase Assay Kit (Clontech) according to 
manufacturer’s instruction in conjunction with the CCD imaging system  (IVIS100 
imaging station; Caliper Life Sciences GmbH, Russelsheim, Germany) in 96-well 
plates. The transfection efficiency internal control was carried out by quantifying pCBR 
mediated intracellular click beetle luciferase activity (CBRLuc) after thawing the frozen 
cell samples. CBRLuc activity was assessed using the Luciferase Assay Kit purchased 
from Promega (Madison, WI, USA) according to manufacturer’s instruction.The 
obtained values were then used to normalize the observed MetLuc activity for the 
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individual transfection efficiency of each well occurring during serial transfections. After 
normalization, the relative light units of pmOCP and pCMVE/mOCP-MetLuc 
transfected samples were calculated relative to the averages obtained for the pMetLuc-
Control positive control samples, representing normalized values promoter activation 
per 24 hours of the reporter construct relative to the constitutive SV40 promoter of the 
pMetLuc-Control vector according to the following equation (Figure 2). 
 
 
Alkaline phosphatase (ALP) activity 
 
Enzymatic alkaline phosphatase assays were employed to additionally assess 
osteogenic differentiation with an established standard method and to test the reporter 
systems interfere with differentiation. The cells were frozen at -80°C prior to 
measurement and then lysed with 100 µl per well of an alkaline ALP-assay buffer (pH 
10.5) containing 0.25% Triton X-100 for 1 hour at room temperature. Enzymatic activity 
was quantified in cleared supernatants after centrifugation by providing 20 mM 
p-nitrophenylphosphate in 50 µl ALP-assay buffer as substrate. 
p-nitrophenylphosphate is converted to p-nitrophenol by ALP, which was quantified by 
its absorbance at 405 nm. The reaction was stopped 20 minutes after addition of the 
substrate with 50 µl of 0.2 M NaOH. The enzymatic activity was then expressed as 
nmoles of p-nitrophenol liberated per minute. 
 
 
Von Kossa staining for mineralization 
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Von Kossa staining for mineralization was carried out after 14 days of differentiation 
(with 300 ng/ml rhBMP2) in order to investigate if the reporter signals overlap with 
centers of mineralization. The cells were washed three times with 1x PBS without 
calcium and magnesium  (Cambrex East Rutherford, NJ, USA). The cells were fixed 
with a 4% aqueous solution of formaldehyde and stained with a 5% (w/w) silvernitrate 
solution for 30 min at room temperature followed by three times washing with ddH2O. 
Development of the staining was carried out with 5% (w/w) Na2CO3 in a 25% aqueous 
solution of formaldehyde followed by three times washing with ddH2O. Final fixation 
was carried out in a 5% (w/w) Na2S2O3 solution in ddH2O for 2 min. After washing the 
cells three times with ddH2O, the staining was observed by phase contrast microscopy. 
 
 
Osteocalcin mRNA expression 
 
Total RNA was isolated from pCMVE/mOCP-MetLuc transfected cells after treatment 
with 0 ng/ml, 100 ng/ml and 300 ng/ml of rhBMP2 using peqGOLD TriFast™ (PeqLab 
Biotechnologie GmBH, Erlangen, Germany) according to manufacturer’s instruction 
(23). 2 µg of total RNA was transcribed to cDNA using an Oligo dT18 primer with an 
AMV-reverse transcriptase (Finnzymes, Espoo, Finland) according to the 
manufacturer’s instructions. 
Quantitative real time PCR for the osteocalcin transcript was carried out with 40 ng of 
total cDNA per reaction using the primers qOC2s (GAACAGACAAGTCCCACACAG) 
and qOC2as (CTGCTTGGACATGAAGGCTTTG) for osteocalcin and qHPRTs 
(AGTCCCAGCGTCGTGATTAG) and qHPRTas (TGGCCTCCCATCTCCTTCAT) for 
the hypoxanthine guanine phosphoribosyl transferase (HPRT) as standard gene using 
the KAPA SYBR Fast qPCR kit (PeqLab Biotechnologie GmBH, Erlangen, Germany) 
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and a Biorad CFX96 real-time PCR cycler. Expression was calculated with relative 
quantification by the comparative CT-method (24). 
 
 
Statistical Analysis 
 
The average ± SEM were calculated for all variables tested. Statistical analysis of 2D 
cell culture data was performed by one-way ANOVA and statistical significance was 
accepted at p<0.05. Statistical analysis of 3D cell culture bioluminescence data was 
performed by Mann-Whitney test. Statistical analysis of ALP-assays, qPCR and the 
bioluminescent data of the direct comparison of pmOCP-MetLuc and pCMVE/mOCP-
MetLuc was carried out using Dunn’s multiple comparison test. 
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Results 
 
Fluorescent osteocalcin reporter gene assay 
 
The pmOCP-EYFPHis reporter plasmid, as expected, exhibited only weak signal 
intensity upon osteogenic differentiation (Figure 3, A) and no detectable background 
signal in the negative control (Figure 3, B). In contrast, strong EYFP fluorescence was 
detectable in C2C12 cells upon osteogenic differentiation 6 days after transient 
transfection with the enhanced reporter pCMVE/mOCP-EYFPHis (Figure 3, C). Only 
weak background signals were observable in the negative myogenic differentiation 
control incubated with DMEM + 1% FCS after 6 days (Figure 3, D).  
 
 
Secreted osteocalcin reporter gene assay in 2D culture 
 
The pCMVE/mOCP-MetLuc reporter system exhibited a strong and concentration 
dependent bioluminescent response to induction with increasing amounts of rhBMP2, 
whereas no activation above negative control background levels was observable upon 
treatment with non-osteoinductive growth factors such as FGF2 and VEGF-A (Figure 
4, A). 
Additionally, a strong correlation was observed between the applied amount of 
osteoinductive growth factor rhBMP2 and the induced expression of Metridia 
Luciferase as quantified by bioluminescence assays (Figure 4, B).  
Furthermore, the mOCP-MetLuc transfected cells also showed a rhBMP2 dose 
dependent induction of bioluminescence signal in the direct comparison with the 
enhanced system (Figure 5), although at approx. 250-fold lower levels than the CMVE-
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enhanced version. Significant signal induction was only detectable in the 300 ng/ml 
treated group for pmOCP-MetLuc. 
 
 
Secreted osteocalcin reporter gene assay in 3D culture 
 
The CMVE/mOCP-MetLuc system exhibited a significant signal increase in the 
rhBMP2 treated group in 3D after 6 days of differentiation (Figure 6) compared to 
negative control clots without rhBMP2 induced osteogenic differentiation. 
 
 
Alkaline phosphatase (ALP) activity 
 
As shown in Figure 7A, the levels of ALP increased with the addition of different 
amounts (50, 100, 300 ng) of rhBMP2. It showed a significant elevation of the p-
nitrophenol signal in the group of 300 ng rhBMP2. There was no induction of ALP 
activity observable in the FGF2 and VEGF-A groups. Furthermore, no difference in 
ALP induction was observable between untransfected, pmOCP-MetLuc transfected 
and pCMVE/mOCP-MetLuc transfected cells as shown in Figure 7B. 
 
 
Von Kossa staining for mineralization 
 
Positive induction of mineralization at cellular condensations was observable in the 
rhBMP2 treated samples (Figure 8, B, C), whereas no mineralization was found in the 
0 ng/ml rhBMP2 control group (Figure 8, D). The observed von Kossa positive centers 
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of mineralization (Figure 8, B) in cellular condensations overlap with the EYFP-positive 
cell clusters (Figure 8, A) in the rhBMP2-induced pCMVE/mOCP-EYFPHis reporter 
system.. 
 
 
Osteocalcin mRNA expression 
 
Quantitative real-time PCR for endogenous osteocalcin mRNA expression in 
pCMVE/mOCP-MetLuc transfected cells (Figure 9) showed a dose dependent 
increase of the osteocalcin transcript and significant induction of osteocalcin 
expression in the 300 ng/ml rhBMP2 treated samples. 
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Discussion 
 
The data obtained in this study strongly suggest that a novel artificial cis-acting 
sequence for osteoblast specific expression has been created by adding a viral 
enhancer element to a specific minimal murine osteocalcin promoter element. Signal 
amplification (approx. up to 250-fold compared to the unenhanced control) of the 
osteocalcin coupled osteoblast specific reporter gene expression was achieved 
through the addition of the CMVE to the proximal promoter without substantially 
impairing the specificity of the mOCP element and with no detectable impact on 
osteogenic differentiation of transfected cells. Furthermore, we were able to 
demonstrate the practicability of a secreted bioluminescent reporter gene Metridia 
luciferase, which allowed detection of osteogenic differentiation through supernatant 
sampling in 2D and 3D cultures. This allows true real-time monitoring of osteogenic 
differentiation, significantly reducing sample numbers. 
 
 
Fluorescent reporter gene assay 
 
 The strong fluorescent signals observed after 6 and 14 days of culturing of 
pCMVE/mOCP-EYFPHis reporter transfected C2C12 cells in osteogenic medium 
(Figure 3C, Figure 8A) were specifically induced in cellular condensations. These 
clusters of transdifferentiated C2C12 cells, were comparable to mesenchymal 
condensations that form during ossification in embryonic development (25), and have 
been confirmed to actually mineralize by von Kossa staining (Figure 8B). Furthermore, 
alkaline phosphatase assays proved that osteogenic differentiation was induced with 
recombinant rhBMP2 (Figure 7). Regarding the overlapping activity of the reporter 
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gene assay with these observations we conclude that the system is specifically 
activated upon osteogenic differentiation. The background activity in myoblastic 
differentiated C2C12 cells, which is independent of osteoblastic differentiation could 
be attributed to the employed CMV-enhancer element, which is capable of binding 
multiple general transcriptional activators present in CMV permissive cells (16). Since 
the observed results suggest that the background expression in the developed assay 
reached only very low levels and expression was specifically enriched in cellular 
clusters undergoing differentiation dependent on the applied amount of osteoinductive 
growth factor, we conclude that the addition of the CMV-enhancer does not impair 
specificity of the system in this specific combination and cellular context. 
Interestingly, sequence analysis (data not shown) showed that the CMVE contains also 
consensus sequences potentially bound by transcription factors associated with 
osteogenic differentiation, such as C/EBP and AP1 (26). Therefore,  it can be assumed 
for the main responsible fact for signal amplification of the mOCP, that the 
enhancement is not exclusively mediated by general expression activation through the 
CMVE without contribution of osteogenic differentiation pathway dependent signalling. 
 
 
 
 
 
 
 
 
Secreted osteocalcin reporter gene assays 
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Metridia luciferase, a secreted luciferase, was employed to modify the initially designed 
fluorescent reporter plasmid for bioluminescence readout to enable supernatant-based 
quantification of the induced reporter gene signals after osteogenic differentiation and 
therefore, to provide a system which will be suitable for application in large-scale 
screening assays as well as for bioreactor construct monitoring. 
This system was tested not only with different concentrations of the osteoinductive 
growth factor rhBMP2 to calculate the correlation of its activity to the amount of rhBMP2 
(Figure 4B) but also with two unrelated growth factors (not osteoinductive in C2C12 
cells) in 2D culture (Figure 4A). The significant increase in signal intensity with 
increasing concentrations of the osteoinductive growth factor rhBMP2 confirmed that 
the designed system is specifically activated upon the induction of endogenous 
osteocalcin expression since a raise in endogenous osteocalcin levels was detected 
in C2C12 cells by qPCR (Figure 9) in accordance with the literature (21). This increase 
in endogenous osteocalcin expression was in parallel to the observed increase in 
reporter system activity. 
The concentration dependent increase of reporter gene expression or 
bioluminescence respectively demonstrates the feasibility of this system to be used in 
bioactivity screening of produced recombinant growth factors and small compounds 
mediating osteoinduction. Using the CMV-enhanced system, it was possible to detect 
osteocalcin expression activating amounts of rhBMP2 down to concentrations of 2 nM 
with a strong linear correlation observed within a range of 2-10 nM (Figure 4B). The 
systems practical implementation for growth factor bioactivity assays for release 
kinetics from novel biomaterials has already been demonstrated (29). 
Although other reporter gene approaches such as the BRE-Luc system have been 
developed (27) that are far more sensitive for BMP growth factor testing (from pM up 
to nM concentration) than the devised method, it is the first approach that employs 
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highly sensitive non-invasive osteocalcin expression monitoring. Therefore, in contrast 
to the above described methods that are very suitable for growth factor bioassays, this 
system allows to monitor bioactivity and osteoinductivity of many different 
osteoinductive substances not limited to a growth factor family since osteocalcin is the 
downstream target of Runx2, the osteogenic master regulatory transcription factor, 
where many osteoinductive signalling pathways converge (28). Through this 
interconnection our assay is not limited to a certain growth factor family. Its activation 
is differentiation specific and not signalling cascade specific. . 
The MetLuc modified system was also tested in 3D culture with C2C12 cells embedded 
into a hydrogel matrix in order to assess the suitability of MetLuc for real-time 
bioreactor monitoring. MetLuc was discharged into the surrounding medium from the 
tissue-like constructs and osteoinduction could be detected. Specific activation of the 
system in 3D culture was demonstrated by the significant increase in MetLuc activity 
(Figure 6) in the supernatant of rhBMP2 treated clots compared to the negative 
controls. Therefore, this novel reporter gene is ideal for the proposed purpose, 
because it is not limited by the employed scaffolding system of the tissue-like 
constructs and easily diffusing into the surrounding medium, where it can be assessed 
without manipulating or destroying the construct.  
 
 
 
 
 
Impact on osteogenic differentiation 
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Since the developed systems exploit the activation of the osteocalcin promoter for 
signal generation, a negative impact of the transfected heterologous osteocalcin 
promoter on endogenous osteocalcin expression could occur that in turn can impair 
differentiation of reporter-transfected cells. ALP-assays showed that there was no 
significant alteration of ALP-activity associated with reporter transfection (Figure 7, B). 
Osteocalcin qPCR in pCMVE/mOCP-MetLuc transfected cells has shown potent (100 
fold) induction of osteocalcin expression through application of 300 ng/ml rhBMP2 
(Figure 9), suggesting no direct impact of the system on endogenous osteocalcin 
expression in C2C12 cells. Von Kossa staining furthermore showed effective 
mineralization after 14 days of differentiation of pCMVE/mOCP-EYFPHis transfected 
cells (Figure 8B), proving their ability to retain the mineralizing phenotype after reporter 
transfection. Therefore, we conclude that the pCMVE/mOCP reporter systems do not 
impair osteogenic differentiation as defined by the observed parameters, 
 
 
Signal amplification and specificity 
 
The cytomegaloviral enhancer has been used to amplify expression from several 
tissue specific promoters with fair results concerning the maintenance of tissue 
specificity. So far this has been successfully demonstrated with neuronal (17), cardiac 
and lung tissue (19) specific constructs but not for bone tissue specific signal 
amplification. This work represents another CMV-enhanced version of a tissue specific 
promoter suitable for restricted expression to be added to this collection of chimeric 
promoter elements that retain their specificity.  
Nevertheless, there is general consensus that there is always the risk of impairing or 
even abolishing the tissue specificity of the employed tissue specific promoter by using 
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this strategy for signal amplification (19) depending on the employed promoter and the 
cellular context (CMV permissive or non-permissive cell type, active signal 
transduction cascades, etc). Therefore, the tissue specificity of novel hybrid constructs 
that contain a CMVE has to be assessed carefully in order to reveal and estimate 
potential background activity limiting the future application of the designed system. 
Concerning the bone specific hybrid CMVE and osteocalcin promoter system it is very 
unlikely that there might be unspecific activation by other growth factors, since there 
was no activation of the system above background levels observable in the unrelated 
growth factor controls FGF2 and VEGF-A. Therefore, it can be assumed that there is 
no substantial reduction of tissue specificity occurring within our system regarding 
potential activation of the CMVE by other growth factor signal transduction cascades.  
 
Future work will include the generation of a CMVE/mOCP-MetLuc and CMVE/mOCP-
EYFPHis stable cell line to further enhance the practicability of the system (elimination 
of the transfection step; all cells in the assay are responsive cells) and potentially its 
sensitivity (through multi-copy insertion of the reporter cassette) as well as the 
application of the MetLuc version in mesenchymal stem cells in a bioreactor for bone 
tissue engineering. 
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Figure 1: pCMVE/mOCP-EYFPHis fluorescent reporter plasmid (A) and pCMVE/mOCP-MetLuc 
bioluminescent reporter plasmid (B). pmOCP-EYFPHis unamplified fluorescent reporter plasmid (C) and 
pmOCP-MetLuc unamplified bioluminescent reporter plasmid (D). The Cytomegalovirus immediate 
early enhancer (CMVE) is depicted in light blue, the minimal osteocalcin2 promoter in dark blue. The 
enhanced yellow fluorescent reporter gene (EYFPHis) is shown in green, the Metridia luciferase 
(MetLuc) reporter gene in orange. 
 
 
 
 
Figure 2: Equation used to calculate the relative activation of the reporter systems using the 
bioluminescence values of 2 different luciferase enzymes detected through the CCD-imaging system. 
Individual Metridia luciferase activity of each well is set relative to the internal transfection control Click 
beetle luciferase (CBRLuc) to normalize for varying transfection efficacies in serial transfection. The 
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relative values were then calculated relative to a constitutive Metridia positive control, representing 
normalized values of relative activation of the differentiation specific sequence to the strong constitutive 
SV40 promoter of the pMetLuc-Control vector transfected cells. 
 
 
Figure 3: (A) pmOCP-EYFPHis activation in C2C12 cells cultured in DMEM + 1% FCS, 200 mM L-
glutamine and 500 ng/ml recombinant human bone morphogenetic protein 2. Scale bars represent 
200µm. (B) pmOCP-EYFPHis activation in C2C12 cells cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) + 1% fetal calf serum (FCS) and 200 mM L-glutamine as negative control for 6 days.  
(C) pCMVE/mOCP-EYFPHis activation in C2C12 cells undergoing osteogenic differentiation. The cells 
were cultured in Dulbecco’s Modified Eagles Medium + 1% fetal calf serum and 200 mM L-glutamine 
for 6 days. Osteogenic transdifferentiation of C2C12 cells was induced with 500 ng/ml of recombinant 
human bone morphogenetic protein 2. The systems specific and strong activation upon osteogenic 
differentiation and osteocalcin promoter activation is observable by the green fluorescent signal emitted 
by the reporter gene enhanced yellow fluorescent protein (EYFPHis) at 520 nm. (D) pCMVE/mOCP-
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EYFPHis activation in C2C12 cells cultured in Dulbecco’s Modified Eagles Medium + 1% fetal calf serum 
and 200 mM L-glutamine as negative control for 6 days. Successful myogenic differentiation is 
observable by the multinuclear myotube phenotype. The systems unspecific background activity levels 
are observable by the green fluorescence of the enhanced yellow fluorescent protein (EYFPHis) 
emission at 520 nm. Scale bars represent 500 µm. 
 
 
Figure 4: (A) Activation of the pCMVE/mOCP-MetLuc enhanced bioluminescent osteocalcin reporter 
system upon induction with different growth factors in 2D culture. A significant induction of Metridia 
Luciferase expression was observable in cells treated with osteoinductive recombinant human bone 
morphogenetic protein 2 (BMP-2). No activation was observable in samples treated with the growth 
factor controls human basic fibroblast growth factor 2 (FGF-2) or human vascular endothelial growth 
factor A (VEGF-A). n = 6, values represent average ± standard deviation.  
(B) Correlation between the applied nanomolar (nM) concentration of recombinant human bone 
morphogenetic protein 2 (BMP-2) and the activation of the pCMVE/mOCP-MetLuc enhanced 
bioluminescent reporter system assuming an approximate molecular weight of 30 kDA for BMP-2. n=6, 
values represent average ± standard deviation. 
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Figure 5: Direct comparison of bioluminescence readouts for the enhanced (CMVE/mOCP) and the 
unenhanced (mOCP) reporter systems in response to 0ng/ml, 100ng/ml and 300ng/ml rhBMP2. 
Readouts are depicted as relative expression levels (fold expression) to the constitutive SV40 promoter. 
mOCP expression levels additionally provided in separate box due to scaling. CMVE/mOCP expression 
levels are approximately 250-fold higher than mOCP expression levels. n=6, values represent average 
± standard deviation. 
 
 
Figure 6: Activity of the CMVE/mOCP-MetLuc reporter system in fibrin clots represented as 
photons/sec/cm
2
 luciferase activity detected in the supernatants. Osteogenic differentiation (left), 
negative control (right). n = 4, values represent average ± standard deviation.  
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Figure 7: Enzymatic alkaline phosphatase (ALP) assay results in 2D culture.  
(A) Liberation of p-Nitrophenol per minute in samples treated with different amounts of recombinant 
human bone morphogenetic protein 2 (BMP-2) and control growth factors. n = 6, values represent 
average ± standard deviation. (B) Comparison of ALP-activities of untransfected (mock), pmOCP-
MetLuc transfected (mOCP) and pCMVE/mOCP-MetLuc transfected cells (CMVE/mOCP). n = 4, values 
represent average ± standard deviation. 
 
 32 
 
Figure 8: (A) pCMVE/mOCP-EYFPHis fluorescence signal after 14 days of differentiation with 300ng/ml 
rhBMP2. (B) Same field of view after von Kossa staining for mineralization, centers of mineralization 
(arrows) overlap with fluorescent signals in A. (C) Positive control after 14 days of differentiation with 
300ng/ml rhBMP2 stained with von Kossa. (D) Negative control von Kossa staining after 14 days. Scale 
bars represent 200µm. 
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Figure 9: Osteocalcin expression levels in pCMVE/mOCP transfected cells (6 days of differentiation) 
as determined by quantitative real-time PCR (relative quantification with comparative Ct-method) in 
response to 0ng/ml, 100ng/ml and 300ng/ml rhBMP2. Readouts are depicted as fold changes of 
osteocalcin normalized to HPRT gene expression in logarithmic scaling. Values represent average ± 
standard deviation. n = 5 for 0ng/ml, n = 4 for 100ng/ml and n = 5 for 300ng/ml of applied rhBMP2.  
 
 
 
